ArticleCase reports in medicine2026
Renal Cell Carcinoma With Hemangioblastoma-Like Features, Fibromyomatous Stroma, and TSC1 Mutation.
Article in Case reports in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal Cell Carcinoma With Hemangioblastoma-Like Features, Fibromyomatous Stroma, and TSC1 Mutation.Case reports in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) with fibromyomatous stroma (RCC-FMS) was classified as an "emerging/provisional" entity in the 2016 WHO classification of tumors, specifically categorized as RCC with (vascular) fibromyomatous stroma. However, it was not included in the 2022 WHO classification. Renal cell carcinoma with hemangioblastoma (RCC-HB)-like features has also been reported infrequently in recent years. RCC-HB-like features and fibromyomatous stroma is quite rare, with only two reports in the literature. This report describes a rare tumor of RCC-HB-like features and fibromyomatous stroma associated with TSC1 mutations. A female patient was incidentally discovered a right renal mass during a routine physical examination conducted 2 weeks prior. Histology revealed that the tumor consisted of three distinct components: clear cell papillary renal cell tumor (CCPRCT)-like areas, fibromyomatous stroma, and HB-like areas. Immunohistochemical staining showed that the CCPRCT-like components exhibited basolateral, cup-shaped CAIX staining and were diffusely positive for AE1/AE3, CK7, and PAX-8, partially positive for AMACR/P504S, and weakly positive for CD10. The fibromyomatous stroma was positive for H-caldesmon, desmin, and SMA. In the HB-like components, α-inhibin, ERG, CD34, CAIX, and vimentin were all diffusely positive, CD10 was partially positive, and PAX-8 showed scattered, weak positivity. Whether RCC-HB features and fibromyomatous stroma can be regarded as a distinct subtype of RCC remains to be discussed by accumulation of more cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.